Scott Ward Acquires 73,255 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) Director Scott Ward bought 73,255 shares of the stock in a transaction on Thursday, May 7th. The shares were bought at an average price of $1.15 per share, for a total transaction of $84,243.25. Following the acquisition, the director owned 237,096 shares in the company, valued at $272,660.40. The trade was a 44.71% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

InspireMD Stock Performance

Shares of NYSE:NSPR opened at $1.15 on Friday. The business’s fifty day moving average price is $1.51 and its two-hundred day moving average price is $1.75. The stock has a market cap of $53.93 million, a PE ratio of -1.53 and a beta of 0.82. InspireMD, Inc. has a one year low of $1.02 and a one year high of $2.93.

Analyst Ratings Changes

NSPR has been the topic of a number of recent research reports. Maxim Group initiated coverage on shares of InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Piper Sandler restated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday. Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Finally, Lake Street Capital set a $4.00 price target on InspireMD in a report on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $4.50.

Institutional Trading of InspireMD

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NSPR. Aberdeen Group plc purchased a new stake in InspireMD in the 3rd quarter valued at about $5,979,000. Rosalind Advisors Inc. grew its holdings in InspireMD by 70.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after buying an additional 1,616,644 shares during the period. Velan Capital Investment Management LP grew its holdings in InspireMD by 137.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after buying an additional 1,239,669 shares during the period. Parkman Healthcare Partners LLC grew its holdings in InspireMD by 97.6% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after buying an additional 1,205,328 shares during the period. Finally, Nantahala Capital Management LLC grew its holdings in InspireMD by 45.7% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after buying an additional 1,058,467 shares during the period. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.